{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:45:49Z","timestamp":1793148349533,"version":"4.5.0"},"reference-count":229,"publisher":"American Society of Hematology","issue":"22","license":[{"start":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T00:00:00Z","timestamp":1772582400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2026,5,28]]},"abstract":"<jats:sec>\n                    <jats:title>Abstract<\/jats:title>\n                    <jats:p>Breakthroughs in cancer immunotherapy have redefined patient care, ushering in a new era of therapeutic modalities, chimeric antigen receptor T cells (CAR-T), and bispecific T-cell engagers, among others. Hemophagocytic lymphohistiocytosis (HLH)\u2013like toxicities triggered by these immunotherapies are increasingly recognized as part of a broader category of hyperinflammatory syndromes. The recently defined immune effector cell\u2013associated HLH-like syndrome (IEC-HS), characterized by hallmark clinical and biochemical features of secondary HLH, is both clinically and temporally distinct from cytokine release syndrome (CRS), typically emerging as CRS subsides or after it has resolved. In contrast, in CRS with multiorgan dysfunction (CRS-MOD), HLH-like manifestations often appear with worsening CRS and progress through standard CRS-directed therapy. Importantly, CRS-MOD is to be differentiated from the acute hyperferritinemia and transient organ toxicities seen with CRS, which often responds to standard CRS management. Clinically differentiating these HLH-like syndromes remains challenging; however, their shared pathophysiology has contributed to an evolving landscape of therapeutic strategies. Given the association of HLH-like toxicities with poor outcomes, enhanced recognition, comprehensive diagnostic approaches, and early intervention strategies may improve outcomes, preserving the potential benefit of the therapies patients are receiving. In this article, we highlight our collective approach in managing 2 recognized CAR-associated HLH-like toxicity syndromes, CRS-MOD and IEC-HS, and provide an overview of the current treatment landscape.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1182\/blood.2025032352","type":"journal-article","created":{"date-parts":[[2026,3,4]],"date-time":"2026-03-04T18:29:54Z","timestamp":1772648994000},"page":"2592-2609","update-policy":"https:\/\/doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":10,"title":["How I treat HLH-like toxicities after immune effector cell therapy"],"prefix":"10.1182","volume":"147","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1514-1095","authenticated-orcid":false,"given":"William T.","family":"Johnson","sequence":"first","affiliation":[{"name":"1Lymphoma Service and Cellular Therapy Service, Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4359-3569","authenticated-orcid":false,"given":"Kevin O.","family":"McNerney","sequence":"additional","affiliation":[{"name":"2Division of Hematology, Oncology, and Stem Cell Transplantation, Ann & Robert H. Lurie Children's Hospital, Chicago, IL"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2356-3354","authenticated-orcid":false,"given":"Matthew J.","family":"Frank","sequence":"additional","affiliation":[{"name":"3Division of Blood and Marrow Transplantation and Cellular Therapy, Department of Medicine, Stanford University, Stanford, CA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8474-9080","authenticated-orcid":false,"given":"Nirali N.","family":"Shah","sequence":"additional","affiliation":[{"name":"4Pediatric Oncology Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"234","reference":[{"issue":"21","key":"2026052811220605500_bib1","doi-asserted-by":"crossref","first-page":"2296","DOI":"10.1182\/blood.V124.21.2296.2296","article-title":"Refractory cytokine release syndrome in recipients of chimeric antigen receptor (CAR) T cells","volume":"124","author":"Frey","year":"2014","journal-title":"Blood"},{"issue":"303","key":"2026052811220605500_bib2","doi-asserted-by":"crossref","first-page":"303ra139","DOI":"10.1126\/scitranslmed.aac5415","article-title":"Chimeric antigen receptor T cells persist and induce sustained remissions in relapsed refractory chronic lymphocytic leukemia","volume":"7","author":"Porter","year":"2015","journal-title":"Sci Transl Med"},{"issue":"6","key":"2026052811220605500_bib3","doi-asserted-by":"crossref","first-page":"664","DOI":"10.1158\/2159-8290.CD-16-0040","article-title":"Identification of predictive biomarkers for cytokine release syndrome after chimeric antigen receptor T-cell therapy for acute lymphoblastic leukemia","volume":"6","author":"Teachey","year":"2016","journal-title":"Cancer Discov"},{"issue":"2","key":"2026052811220605500_bib4","doi-asserted-by":"crossref","first-page":"e124","DOI":"10.1097\/CCM.0000000000002053","article-title":"Cytokine release syndrome after chimeric antigen receptor T cell therapy for acute lymphoblastic leukemia","volume":"45","author":"Fitzgerald","year":"2017","journal-title":"Crit Care Med"},{"issue":"1","key":"2026052811220605500_bib5","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1038\/nrclinonc.2017.148","article-title":"Chimeric antigen receptor T-cell therapy \u2014 assessment and management of toxicities","volume":"15","author":"Neelapu","year":"2018","journal-title":"Nat Rev Clin Oncol"},{"issue":"suppl 15","key":"2026052811220605500_bib6","doi-asserted-by":"crossref","first-page":"8057","DOI":"10.1200\/JCO.2020.38.15_suppl.8057","article-title":"Haemophagocytic lymphohistiocytosis (HLH) in patients with large B-cell lymphoma treated with standard of care (SOC) axicabtagene ciloleucel (Axi-cel)","volume":"38","author":"Ahmed","year":"2020","journal-title":"J Clin Oncol"},{"issue":"12","key":"2026052811220605500_bib7","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1182\/bloodadvances.2022008893","article-title":"HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL","volume":"7","author":"McNerney","year":"2023","journal-title":"Blood Adv"},{"key":"2026052811220605500_bib8","unstructured":"Kymriah. Package insert and medication guide. Food and Drug Administration. Accessed 30 December 2024. https:\/\/www.fda.gov\/media\/107296\/download."},{"key":"2026052811220605500_bib9","unstructured":"Yescarta. Package insert and medication guide. Food and Drug Administration. Accessed 30 December 2024. https:\/\/www.fda.gov\/media\/108377\/download."},{"key":"2026052811220605500_bib10","unstructured":"Breyanzi. Package insert and medication guide. Food and Drug Administration. Accessed 30 December 2024. https:\/\/www.fda.gov\/media\/145711\/download."},{"key":"2026052811220605500_bib11","unstructured":"Tecartus. Package insert and medication guide. Food and Drug Administration. Accessed 30 December 2024. https:\/\/www.fda.gov\/media\/140409\/download."},{"key":"2026052811220605500_bib12","unstructured":"Abecma. Package insert and medication guide. Food and Drug Administration. Accessed 30 December 2024. https:\/\/www.fda.gov\/media\/147055\/download."},{"key":"2026052811220605500_bib13","unstructured":"Carvykti. Package insert and medication guide. Food and Drug Administration. Accessed 30 December 2024. https:\/\/www.fda.gov\/media\/156560\/download."},{"key":"2026052811220605500_bib14","unstructured":"Aucatzyl. Package insert and medication guide. Food and Drug Administration. Accessed 1 March 2025. https:\/\/www.fda.gov\/media\/183463\/download."},{"issue":"17","key":"2026052811220605500_bib15","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1200\/JCO.19.03279","article-title":"CD4\/CD8 T-cell selection affects chimeric antigen receptor (CAR) T-cell potency and toxicity: updated results from a phase I anti-CD22 CAR T-cell trial","volume":"38","author":"Shah","year":"2020","journal-title":"J Clin Oncol"},{"issue":"27","key":"2026052811220605500_bib16","doi-asserted-by":"crossref","first-page":"3095","DOI":"10.1200\/JCO.19.02103","article-title":"Axicabtagene ciloleucel in the non-trial setting: outcomes and correlates of response, resistance, and toxicity","volume":"38","author":"Jacobson","year":"2020","journal-title":"J Clin Oncol"},{"issue":"23","key":"2026052811220605500_bib17","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1182\/bloodadvances.2021005020","article-title":"Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma","volume":"5","author":"Kennedy","year":"2021","journal-title":"Blood Adv"},{"issue":"7","key":"2026052811220605500_bib18","first-page":"438.e1","article-title":"Immune effector cell associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transpl Cell Ther"},{"key":"2026052811220605500_bib19","unstructured":"National Comprehensive Cancer Network\n          . NCCN Clinical Practice Guidelines in Oncology: Management of CAR T-Cell-Related Toxicities. Version 1.2025. Accessed 20 March 2026. https:\/\/www.nccn.org\/professionals\/physician_gls\/pdf\/immunotherapy.pdf."},{"issue":"20","key":"2026052811220605500_bib20","first-page":"2430","article-title":"How I treat refractory CRS and ICANS after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"10","key":"2026052811220605500_bib21","doi-asserted-by":"crossref","first-page":"865","DOI":"10.1182\/blood.2023020578","article-title":"Immune effector cell-associated hematotoxicity: EHA\/EBMT consensus grading and best practice recommendations","volume":"142","author":"Rejeski","year":"2023","journal-title":"Blood"},{"issue":"21","key":"2026052811220605500_bib22","doi-asserted-by":"crossref","first-page":"5149","DOI":"10.3390\/cancers15215149","article-title":"Immune effector cell-associated HLH-like syndrome: a review of the literature of an increasingly recognized entity","volume":"15","author":"Fugere","year":"2023","journal-title":"Cancers (Basel)"},{"issue":"1","key":"2026052811220605500_bib23","first-page":"38","article-title":"INSPIRED symposium part 3: prevention and management of pediatric chimeric antigen receptor T cell-associated emergent toxicities","volume":"30","author":"McNerney","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"8","key":"2026052811220605500_bib24","doi-asserted-by":"crossref","first-page":"e374","DOI":"10.1016\/S1470-2045(24)00094-9","article-title":"Consensus guidelines and recommendations for the management and response assessment of chimeric antigen receptor T-cell therapy in clinical practice for relapsed and refractory multiple myeloma: a report from the International Myeloma Working Group Immunotherapy Committee","volume":"25","author":"Lin","year":"2024","journal-title":"Lancet Oncol"},{"issue":"3-4","key":"2026052811220605500_bib25","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1007\/s00281-024-01013-w","article-title":"Riding the storm: managing cytokine-related toxicities in CAR-T cell therapy","volume":"46","author":"Hughes","year":"2024","journal-title":"Semin Immunopathol"},{"issue":"16","key":"2026052811220605500_bib26","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1182\/blood.2023022432","article-title":"Consensus recommendations on the management of toxicity associated with CD3\u00d7CD20 bispecific antibody therapy","volume":"143","author":"Crombie","year":"2024","journal-title":"Blood"},{"issue":"3","key":"2026052811220605500_bib27","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1080\/14656566.2024.2340738","article-title":"Current and emerging pharmacotherapies for cytokine release syndrome, neurotoxicity, and hemophagocytic lymphohistiocytosis-like syndrome due to CAR T cell therapy","volume":"25","author":"Walton","year":"2024","journal-title":"Expert Opin Pharmacother"},{"issue":"3","key":"2026052811220605500_bib28","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1080\/1744666X.2024.2444673","article-title":"Hemophagocytic lymphohistiocytosis post chimeric antigen receptor T cell therapies","volume":"21","author":"Wang","year":"2025","journal-title":"Expert Rev Clin Immunol"},{"issue":"6","key":"2026052811220605500_bib29","doi-asserted-by":"crossref","first-page":"e459","DOI":"10.1016\/S2352-3026(24)00077-2","article-title":"Immune effector cell-associated haematotoxicity after CAR T-cell therapy: from mechanism to management","volume":"11","author":"Rejeski","year":"2024","journal-title":"Lancet Haematol"},{"issue":"6","key":"2026052811220605500_bib30","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/s41409-025-02567-5","article-title":"Less frequent complications following CAR T-cell therapies: hemophagocytic lymphohistiocytosis, graft-versus-host disease, thrombotic microangiopathy, coagulation disorders and secondary malignancies: best practice recommendations from the EBMT Practice Harmonization and Guidelines Committee","volume":"60","author":"Ort\u00ed","year":"2025","journal-title":"Bone Marrow Transpl"},{"issue":"3","key":"2026052811220605500_bib31","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.hoc.2025.02.005","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS)","volume":"39","author":"Lee","year":"2025","journal-title":"Hematol Oncol Clin North Am"},{"key":"2026052811220605500_bib32","unstructured":"National Cancer Institute\n          . Common Terminology Criteria for Adverse Events (CTCAE). Version 5.0. Accessed 31 December 2024. https:\/\/ctep.cancer.gov\/protocoldevelopment\/electronic_applications\/docs\/ctcae_v5_quick_reference_5x7.pdf."},{"issue":"5","key":"2026052811220605500_bib33","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/1043-4666(92)90078-6","article-title":"Pharmacokinetics, safety and immunomodulatory effects of human recombinant interleukin-1 receptor antagonist in healthy humans","volume":"4","author":"Granowitz","year":"1992","journal-title":"Cytokine"},{"issue":"6","key":"2026052811220605500_bib34","doi-asserted-by":"crossref","first-page":"394","DOI":"10.1016\/j.smim.2013.10.023","article-title":"The interleukin-1 receptor family","volume":"25","author":"Boraschi","year":"2013","journal-title":"Semin Immunol"},{"issue":"1","key":"2026052811220605500_bib35","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1111\/imr.12621","article-title":"Overview of the IL-1 family in innate inflammation and acquired immunity","volume":"281","author":"Dinarello","year":"2018","journal-title":"Immunol Rev"},{"key":"2026052811220605500_bib36","doi-asserted-by":"crossref","first-page":"888392","DOI":"10.3389\/fimmu.2022.888392","article-title":"Systematic review of safety and efficacy of IL-1-targeted biologics in treating immune-mediated disorders","volume":"13","author":"Arnold","year":"2022","journal-title":"Front Immunol"},{"issue":"7","key":"2026052811220605500_bib37","first-page":"438.e1","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome","volume":"29","author":"Hines","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"3","key":"2026052811220605500_bib38","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1182\/blood-2003-10-3413","article-title":"An animal model of hemophagocytic lymphohistiocytosis (HLH): CD8+ T cells and interferon gamma are essential for the disorder","volume":"104","author":"Jordan","year":"2004","journal-title":"Blood"},{"issue":"1","key":"2026052811220605500_bib39","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1111\/imr.12768","article-title":"Cellular therapy: immune-related complications","volume":"290","author":"Oved","year":"2019","journal-title":"Immunol Rev"},{"issue":"10","key":"2026052811220605500_bib40","doi-asserted-by":"crossref","first-page":"5425","DOI":"10.1172\/JCI130059","article-title":"Perforin-deficient CAR T cells recapitulate late-onset inflammatory toxicities observed in patients","volume":"130","author":"Ishii","year":"2020","journal-title":"J Clin Invest"},{"issue":"19","key":"2026052811220605500_bib41","doi-asserted-by":"crossref","first-page":"4898","DOI":"10.1182\/bloodadvances.2020002394","article-title":"Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma","volume":"4","author":"Locke","year":"2020","journal-title":"Blood Adv"},{"issue":"19","key":"2026052811220605500_bib42","doi-asserted-by":"crossref","first-page":"2621","DOI":"10.1182\/blood.2020007445","article-title":"Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma","volume":"137","author":"Jain","year":"2021","journal-title":"Blood"},{"issue":"17","key":"2026052811220605500_bib43","doi-asserted-by":"crossref","first-page":"3804","DOI":"10.1158\/1078-0432.CCR-22-0822","article-title":"Comprehensive serum proteome profiling of cytokine release syndrome and immune effector cell-associated neurotoxicity syndrome patients with B-cell ALL receiving CAR T19","volume":"28","author":"Diorio","year":"2022","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2026052811220605500_bib44","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.jcyt.2022.11.001","article-title":"Cytokine profiles are associated with prolonged hematologic toxicities after B-cell maturation antigen targeted chimeric antigen receptor-T-cell therapy","volume":"25","author":"Wang","year":"2023","journal-title":"Cytotherapy"},{"issue":"2","key":"2026052811220605500_bib45","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1038\/s41591-023-02754-1","article-title":"Impact of tumor microenvironment on efficacy of anti-CD19 CAR T cell therapy or chemotherapy and transplant in large B cell lymphoma","volume":"30","author":"Locke","year":"2024","journal-title":"Nat Med"},{"issue":"suppl 1","key":"2026052811220605500_bib46","doi-asserted-by":"crossref","first-page":"7165","DOI":"10.1182\/blood-2024-211111","article-title":"Cytokine profile comparisons among cytokine release syndrome (CRS), macrophage activation-like syndrome (MAS-L) and immune effector cell-associated hemophagocytic syndrome (IEC-HS) in CAR-T therapy [abstract]","volume":"144","author":"Gupta","year":"2024","journal-title":"Blood"},{"issue":"6","key":"2026052811220605500_bib47","doi-asserted-by":"crossref","first-page":"2264","DOI":"10.1172\/JCI43157","article-title":"Repeated TLR9 stimulation results in macrophage activation syndrome-like disease in mice","volume":"121","author":"Behrens","year":"2011","journal-title":"J Clin Invest"},{"issue":"1","key":"2026052811220605500_bib48","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/annrheumdis-2015-209020","article-title":"Elevated circulating levels of interferon-\u03b3 and interferon-\u03b3-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"76","author":"Bracaglia","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"71","key":"2026052811220605500_bib49","doi-asserted-by":"crossref","first-page":"eabo1303","DOI":"10.1126\/sciimmunol.abo1303","article-title":"Understanding T cell responses to COVID-19 is essential for informing public health strategies","volume":"7","author":"Vardhana","year":"2022","journal-title":"Sci Immunol"},{"issue":"6","key":"2026052811220605500_bib50","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1056\/NEJMra2314005","article-title":"Hemophagocytic lymphohistiocytosis","volume":"392","author":"Henter","year":"2025","journal-title":"N Engl J Med"},{"issue":"8","key":"2026052811220605500_bib51","doi-asserted-by":"crossref","first-page":"5107","DOI":"10.4049\/jimmunol.0803468","article-title":"Pathogenesis of steroid-resistant airway hyperresponsiveness: interaction between IFN gamma and TLR4\/MyD88 pathways","volume":"182","author":"Yang","year":"2009","journal-title":"J Immunol"},{"issue":"9678","key":"2026052811220605500_bib52","doi-asserted-by":"crossref","first-page":"1905","DOI":"10.1016\/S0140-6736(09)60326-3","article-title":"Glucocorticoid resistance in inflammatory diseases","volume":"373","author":"Barnes","year":"2009","journal-title":"The Lancet"},{"issue":"1","key":"2026052811220605500_bib53","doi-asserted-by":"crossref","first-page":"L71","DOI":"10.1152\/ajplung.00547.2017","article-title":"Th1 cytokines TNF-\u03b1 and IFN-\u03b3 promote corticosteroid resistance in developing human airway smooth muscle","volume":"316","author":"Britt","year":"2019","journal-title":"Am J Physiol Lung Cell Mol Physiol"},{"issue":"11","key":"2026052811220605500_bib54","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1016\/j.jcyt.2023.06.008","article-title":"A distinct cytokine network distinguishes chimeric antigen receptor T cell (CAR-T)-associated hemophagocytic lymphohistiocytosis-like toxicity (carHLH) from severe cytokine release syndrome following CAR-T therapy","volume":"25","author":"Zu","year":"2023","journal-title":"Cytotherapy"},{"issue":"20","key":"2026052811220605500_bib55","doi-asserted-by":"crossref","first-page":"6134","DOI":"10.1182\/bloodadvances.2023010708","article-title":"Free interleukin-18 is elevated in CD22 CAR T-cell associated hemophagocytic lymphohistiocytosis-like toxicities","volume":"7","author":"Rocco","year":"2023","journal-title":"Blood Adv"},{"issue":"18","key":"2026052811220605500_bib56","doi-asserted-by":"crossref","first-page":"4823","DOI":"10.1158\/1078-0432.CCR-20-1434","article-title":"Tumor microenvironment composition and severe cytokine release syndrome (CRS) influence toxicity in patients with large B-cell lymphoma treated with axicabtagene ciloleucel","volume":"26","author":"Faramand","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"5","key":"2026052811220605500_bib57","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/bloodadvances.2019001272","article-title":"Identification of germline variants in adults with hemophagocytic lymphohistiocytosis","volume":"4","author":"Miller","year":"2020","journal-title":"Blood Adv"},{"issue":"24","key":"2026052811220605500_bib58","doi-asserted-by":"crossref","first-page":"2499","DOI":"10.1182\/blood.2020010543","article-title":"CAR-HEMATOTOX: a model for CAR T-cell-related hematologic toxicity in relapsed\/refractory large B-cell lymphoma","volume":"138","author":"Rejeski","year":"2021","journal-title":"Blood"},{"issue":"10","key":"2026052811220605500_bib59","doi-asserted-by":"crossref","first-page":"e009220","DOI":"10.1136\/jitc-2024-009220","article-title":"EASIX-guided risk stratification for complications and outcome after CAR T-cell therapy with ide-cel in relapsed\/refractory multiple myeloma","volume":"12","author":"Frenking","year":"2024","journal-title":"J Immunother Cancer"},{"issue":"2","key":"2026052811220605500_bib60","doi-asserted-by":"crossref","first-page":"106","DOI":"10.1158\/2643-3230.BCD-23-0056","article-title":"Baseline serum inflammatory proteins predict poor CAR T outcomes in diffuse large B-cell lymphoma","volume":"5","author":"Faramand","year":"2024","journal-title":"Blood Cancer Discov"},{"issue":"2","key":"2026052811220605500_bib61","doi-asserted-by":"crossref","first-page":"270","DOI":"10.1182\/bloodadvances.2024014027","article-title":"EASIX and m-EASIX predict CRS and ICANS in pediatric and AYA patients after CD19-CAR T-cell therapy","volume":"9","author":"Zandaki","year":"2025","journal-title":"Blood Adv"},{"issue":"4","key":"2026052811220605500_bib62","doi-asserted-by":"crossref","first-page":"1183","DOI":"10.1038\/s41591-025-03532-x","article-title":"An inflammatory biomarker signature of response to CAR-T cell therapy in non-Hodgkin lymphoma","volume":"31","author":"Raj","year":"2025","journal-title":"Nat Med"},{"issue":"11","key":"2026052811220605500_bib63","doi-asserted-by":"crossref","first-page":"1136","DOI":"10.1182\/blood.2024025910","article-title":"Development of ALL-Hematotox: predicting post-CAR T-cell hematotoxicity in B-cell acute lymphoblastic leukemia","volume":"145","author":"Nair","year":"2025","journal-title":"Blood"},{"issue":"1","key":"2026052811220605500_bib64","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1182\/bloodadvances.2024014555","article-title":"Cancer cachexia and weight loss before CAR T-cell therapy for lymphoma are independently associated with poor outcomes","volume":"9","author":"Valtis","year":"2025","journal-title":"Blood Adv"},{"issue":"3","key":"2026052811220605500_bib65","doi-asserted-by":"crossref","first-page":"606","DOI":"10.1182\/bloodadvances.2024014455","article-title":"Development and validation of predictive models of early immune effector cell\u2013associated hematotoxicity","volume":"9","author":"Liang","year":"2025","journal-title":"Blood Adv"},{"issue":"7","key":"2026052811220605500_bib66","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1182\/blood.2025028833","article-title":"T-ICAHT: grading and prognostic impact of thrombocytopenia after CAR T-cell therapy","volume":"146","author":"Rejeski","year":"2025","journal-title":"Blood"},{"issue":"3","key":"2026052811220605500_bib67","doi-asserted-by":"crossref","first-page":"146","DOI":"10.14740\/jh2046","article-title":"Ruxolitinib is an effective therapy for ciltacabtagene autoleucel-associated parkinsonism in multiple myeloma","volume":"14","author":"Wirk","year":"2025","journal-title":"J Hematol"},{"issue":"4","key":"2026052811220605500_bib68","first-page":"240.e1","article-title":"Prospective validation of CAR-HEMATOTOX and a simplified version predict survival in patients with large B-cell lymphoma treated with anti-CD19 CAR T-cells: data from CART-SIE study","volume":"31","author":"Stella","year":"2025","journal-title":"Transpl Cell Ther"},{"issue":"10","key":"2026052811220605500_bib69","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.1182\/blood-2014-10-602607","article-title":"Marked hyperferritinemia does not predict for HLH in the adult population","volume":"125","author":"Schram","year":"2015","journal-title":"Blood"},{"issue":"11","key":"2026052811220605500_bib70","doi-asserted-by":"crossref","first-page":"e1045","DOI":"10.1097\/CCM.0000000000001878","article-title":"The use of ferritin to identify critically ill patients with secondary hemophagocytic lymphohistiocytosis","volume":"44","author":"Grang\u00e9","year":"2016","journal-title":"Crit Care Med"},{"issue":"11","key":"2026052811220605500_bib71","doi-asserted-by":"crossref","first-page":"e27929","DOI":"10.1002\/pbc.27929","article-title":"Challenges in the diagnosis of hemophagocytic lymphohistiocytosis: Recommendations from the North American Consortium for Histiocytosis (NACHO)","volume":"66","author":"Jordan","year":"2019","journal-title":"Pediatr Blood Cancer"},{"issue":"4","key":"2026052811220605500_bib72","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1097\/CCM.0000000000004131","article-title":"Hyperferritinemia in critically ill patients","volume":"48","author":"Lachmann","year":"2020","journal-title":"Crit Care Med"},{"issue":"1","key":"2026052811220605500_bib73","doi-asserted-by":"crossref","first-page":"192","DOI":"10.3390\/jcm12010192","article-title":"Differential diagnosis of hyperferritinemia in critically ill patients","volume":"12","author":"Schuster","year":"2022","journal-title":"J Clin Med"},{"issue":"9","key":"2026052811220605500_bib74","doi-asserted-by":"crossref","first-page":"e31171","DOI":"10.1002\/pbc.31171","article-title":"Diagnostic pitfalls in assessment of ferritin following CAR-T-cell therapy: understanding the hook effect","volume":"71","author":"Harb","year":"2024","journal-title":"Pediatr Blood Cancer"},{"issue":"8","key":"2026052811220605500_bib75","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1002\/ajh.20854","article-title":"Florid histiocytic hemophagocytosis following therapy with long acting G-CSF (pegfilgrastim)","volume":"82","author":"Glasser","year":"2007","journal-title":"Am J Hematol"},{"issue":"1","key":"2026052811220605500_bib76","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/asheducation-2015.1.183","article-title":"The unique aspects of presentation and diagnosis of hemophagocytic lymphohistiocytosis in adults","volume":"2015","author":"Nikiforow","year":"2015","journal-title":"Hematology"},{"issue":"5","key":"2026052811220605500_bib77","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1007\/s10875-020-00789-4","article-title":"Thinking beyond HLH: clinical features of patients with concurrent presentation of hemophagocytic lymphohistiocytosis and thrombotic microangiopathy","volume":"40","author":"Gloude","year":"2020","journal-title":"J Clin Immunol"},{"key":"2026052811220605500_bib78","doi-asserted-by":"crossref","DOI":"10.1111\/ijd.15196","article-title":"Overlap between hemophagocytic lymphohistiocytosis and drug reaction and eosinophilia with systemic symptoms: a review","author":"Yang","year":"2021;60:925-932","journal-title":"Int J Dermatol"},{"issue":"6","key":"2026052811220605500_bib79","doi-asserted-by":"crossref","first-page":"901","DOI":"10.1007\/s10875-020-00814-6","article-title":"Neuroinflammatory disease as an isolated manifestation of hemophagocytic lymphohistiocytosis","volume":"40","author":"Blincoe","year":"2020","journal-title":"J Clin Immunol"},{"issue":"1","key":"2026052811220605500_bib80","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1097\/CCM.0000000000005149","article-title":"Critically ill patients treated for chimeric antigen receptor-related toxicity: a multicenter study","volume":"50","author":"Gutierrez","year":"2022","journal-title":"Crit Care Med"},{"issue":"4","key":"2026052811220605500_bib81","doi-asserted-by":"crossref","first-page":"493","DOI":"10.1111\/ejh.14263","article-title":"Marked hyperferritinemia in critically ill cancer patients","volume":"113","author":"Liedgens","year":"2024","journal-title":"Eur J Haematol"},{"issue":"2","key":"2026052811220605500_bib82","doi-asserted-by":"crossref","first-page":"150","DOI":"10.1016\/j.jiac.2023.09.026","article-title":"Filgrastim-induced hemophagocytic lymphohistiocytosis in a patient with mantle cell lymphoma: a case report","volume":"30","author":"Higuchi","year":"2024","journal-title":"J Infect Chemother"},{"issue":"suppl 1","key":"2026052811220605500_bib83","doi-asserted-by":"crossref","first-page":"5373","DOI":"10.1182\/blood-2024-202475","article-title":"Lamotrigine and anti-epileptic medications in HLH: a systematic review [abstract]","volume":"144","author":"Gummadi","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026052811220605500_bib84","doi-asserted-by":"crossref","first-page":"5380","DOI":"10.1182\/blood-2024-210196","article-title":"CXCL-9 and IL-18: potential biomarkers for efficacy evaluation in refractory hemophagocytic lymphohistiocytosis treated with RED (ruxolitinib, emapalumab and dexamethasone) [abstract]","volume":"144","author":"Lan","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026052811220605500_bib85","doi-asserted-by":"crossref","first-page":"e70163","DOI":"10.1111\/cts.70163","article-title":"Emapalumab in patients with macrophage activation syndrome associated with still's disease: a population pharmacokinetic\/pharmacodynamic analysis","volume":"18","author":"Brossard","year":"2025","journal-title":"Clin Transl Sci"},{"issue":"9","key":"2026052811220605500_bib86","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1182\/bloodadvances.2023012217","article-title":"Real-world treatment patterns and outcomes in patients with primary hemophagocytic lymphohistiocytosis treated with emapalumab","volume":"8","author":"Chandrakasan","year":"2024","journal-title":"Blood Adv"},{"issue":"4","key":"2026052811220605500_bib87","doi-asserted-by":"crossref","first-page":"701","DOI":"10.1111\/bjh.17662","article-title":"Hemophagocytic lymphohistiocytosis-like toxicity (carHLH) after CD19-specific CAR T-cell therapy","volume":"194","author":"Hines","year":"2021","journal-title":"Br J Haematol"},{"issue":"6","key":"2026052811220605500_bib88","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1080\/10428194.2021.2024817","article-title":"Low utility of the H-Score and HLH-2004 criteria to identify patients with secondary hemophagocytic lymphohistiocytosis after CAR-T cell therapy for relapsed\/refractory diffuse large B-Cell lymphoma","volume":"63","author":"Kim","year":"2022","journal-title":"Leuk Lymphoma"},{"issue":"10","key":"2026052811220605500_bib89","doi-asserted-by":"crossref","first-page":"E374","DOI":"10.1002\/ajh.26668","article-title":"Hemophagocytic lymphohistiocytosis secondary to CAR-T cells: update from the FDA and Vizient databases","volume":"97","author":"Priyadarshini","year":"2022","journal-title":"Am J Hematol"},{"issue":"17","key":"2026052811220605500_bib90","doi-asserted-by":"crossref","first-page":"4765","DOI":"10.1182\/bloodadvances.2022008937","article-title":"Chimeric antigen receptor T-cell therapy yields similar outcomes in patients with and without cytokine release syndrome","volume":"7","author":"Bhaskar","year":"2023","journal-title":"Blood Adv"},{"issue":"8","key":"2026052811220605500_bib91","doi-asserted-by":"crossref","first-page":"2067","DOI":"10.3324\/haematol.2022.281455","article-title":"Hemophagocytic lymphohistiocytosis and disseminated intravascular coagulation are underestimated, but fatal adverse events in chimeric antigen receptor T-cell therapy","volume":"108","author":"Song","year":"2023","journal-title":"Haematologica"},{"issue":"10450","key":"2026052811220605500_bib92","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0140-6736(24)00746-3","article-title":"CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study","volume":"404","author":"Frank","year":"2024","journal-title":"Lancet"},{"issue":"1","key":"2026052811220605500_bib93","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1038\/s41408-024-01119-2","article-title":"Chimeric antigen receptor T-cell therapy associated hemophagocytic lymphohistiocytosis syndrome: clinical presentation, outcomes, and management","volume":"14","author":"Khurana","year":"2024","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2026052811220605500_bib94","doi-asserted-by":"crossref","first-page":"528","DOI":"10.1182\/blood-2024-208304","article-title":"Hemophagocytic lymphohistiocytosis-like syndrome after anti-CD19 CAR T-cells for B-cell lymphoma and B-cell acute lymphoblastic leukemia: a Lysa, Sfce and Graall Study from the Descar-T registry [abstract]","volume":"144","author":"Gower","year":"2024","journal-title":"Blood"},{"issue":"9","key":"2026052811220605500_bib95","first-page":"876","article-title":"Timing of toxicities and non-relapse mortality following CAR T therapy in myeloma","volume":"30","author":"Wesson","year":"2024","journal-title":"Transpl Cell Ther"},{"issue":"suppl 1","key":"2026052811220605500_bib96","doi-asserted-by":"crossref","first-page":"5163","DOI":"10.1182\/blood-2024-208307","article-title":"Immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) for chimeric antigen receptor T-cell therapy (CAR-T) and T-cell engager antibody (TCE) in myeloma and lymphoma [abstract]","volume":"144","author":"Ayoobkhan","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026052811220605500_bib97","doi-asserted-by":"crossref","first-page":"S241","DOI":"10.1016\/j.jtct.2025.01.368","article-title":"Hyperferritinemia syndromes and their clinical impact in lymphoma patients receiving CD19 CAR-T treatment","volume":"31","author":"Ballweg","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"10450","key":"2026052811220605500_bib98","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1016\/S0140-6736(24)00746-3","article-title":"CD22-directed CAR T-cell therapy for large B-cell lymphomas progressing after CD19-directed CAR T-cell therapy: a dose-finding phase 1 study","volume":"404","author":"Frank","year":"2024","journal-title":"Lancet"},{"issue":"5","key":"2026052811220605500_bib99","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1038\/s41375-024-02220-y","article-title":"CD22 CAR T cells demonstrate high response rates and safety in pediatric and adult B-ALL: phase 1b results","volume":"38","author":"Schultz","year":"2024","journal-title":"Leukemia"},{"issue":"12","key":"2026052811220605500_bib100","doi-asserted-by":"crossref","first-page":"2758","DOI":"10.1182\/bloodadvances.2022008893","article-title":"HLH-like toxicities predict poor survival after the use of tisagenlecleucel in children and young adults with B-ALL","volume":"7","author":"McNerney","year":"2023","journal-title":"Blood Adv"},{"issue":"23","key":"2026052811220605500_bib101","doi-asserted-by":"crossref","first-page":"5344","DOI":"10.1182\/bloodadvances.2021005020","article-title":"Macrophage activation syndrome-like (MAS-L) manifestations following BCMA-directed CAR T cells in multiple myeloma","volume":"5","author":"Kennedy","year":"2021","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026052811220605500_bib102","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1182\/blood-2022-166322","article-title":"Patients with deleterious germline variants in STXBP2 develop toxicity after CAR-T cell therapy with axicabtagene ciloleucel [abstract]","volume":"140","author":"Leick","year":"2022","journal-title":"Blood"},{"issue":"8","key":"2026052811220605500_bib103","doi-asserted-by":"crossref","first-page":"101158","DOI":"10.1016\/j.xcrm.2023.101158","article-title":"Prolonged cytopenia following CD19 CAR T cell therapy is linked with bone marrow infiltration of clonally expanded IFN\u03b3-expressing CD8 T cells","volume":"4","author":"Strati","year":"2023","journal-title":"Cell Rep Med"},{"issue":"11","key":"2026052811220605500_bib104","doi-asserted-by":"crossref","first-page":"2989","DOI":"10.1007\/s00277-023-05271-w","article-title":"Delay in treatment of adult hemophagocytic lymphohistiocytosis is associated with worse in-hospital outcomes","volume":"102","author":"Abdelhay","year":"2023","journal-title":"Ann Hematol"},{"issue":"20","key":"2026052811220605500_bib105","first-page":"2460","article-title":"How I treat cytopenias after CAR T-cell therapy","volume":"141","author":"Jain","year":"2023","journal-title":"Blood"},{"issue":"1","key":"2026052811220605500_bib106","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1186\/s13613-024-01247-9","article-title":"Features and outcomes of patients admitted to the ICU for chimeric antigen receptor T cell-related toxicity: a French multicentre cohort","volume":"14","author":"Le Cacheux","year":"2024","journal-title":"Ann Intensive Care"},{"issue":"9","key":"2026052811220605500_bib107","doi-asserted-by":"crossref","first-page":"2667","DOI":"10.1038\/s41591-024-03084-6","article-title":"A systematic review and meta-analysis of nonrelapse mortality after CAR T cell therapy","volume":"30","author":"Cordas dos Santos","year":"2024","journal-title":"Nat Med"},{"issue":"3","key":"2026052811220605500_bib108","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1016\/j.hoc.2025.02.007","article-title":"Recognizing and managing secondary hemophagocytic lymphohistiocytosis in adults: a practical clinical guide","volume":"39","author":"Zoref-Lorenz","year":"2025","journal-title":"Hematol Oncol Clin North Am"},{"key":"2026052811220605500_bib109","unstructured":"Kineret. Package Insert. Food and Drug Administration. Accessed 19 March 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/103950s5197lbl.pdf."},{"issue":"suppl 6","key":"2026052811220605500_bib110","doi-asserted-by":"crossref","first-page":"vi9","DOI":"10.1093\/rheumatology\/kez350","article-title":"Anakinra in children and adults with Still's disease","volume":"58","author":"Vastert","year":"2019","journal-title":"Rheumatology (Oxford)"},{"issue":"3","key":"2026052811220605500_bib111","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1055\/s-0041-1724113","article-title":"Deficiency of interleukin-1 receptor antagonist: new genetic autoinflammatory disease as a diagnostic challenge for pediatricians","volume":"12","author":"Rivera-Sepulveda","year":"2023","journal-title":"J Pediatr Genet"},{"issue":"7","key":"2026052811220605500_bib112","doi-asserted-by":"crossref","first-page":"2375","DOI":"10.1002\/art.34409","article-title":"Sustained response and prevention of damage progression in patients with neonatal-onset multisystem inflammatory disease treated with anakinra: a cohort study to determine three- and five-year outcomes","volume":"64","author":"Sibley","year":"2012","journal-title":"Arthritis Rheum"},{"issue":"3","key":"2026052811220605500_bib113","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1111\/ejh.14029","article-title":"Intravenous anakinra for the treatment of haemophagocytic lymphohistiocytosis\/macrophage activation syndrome: a systematic review","volume":"111","author":"Charlesworth","year":"2023","journal-title":"Eur J Haematol"},{"issue":"2","key":"2026052811220605500_bib114","doi-asserted-by":"crossref","first-page":"275","DOI":"10.1097\/CCM.0000000000001402","article-title":"Interleukin-1 receptor blockade is associated with reduced mortality in sepsis patients with features of macrophage activation syndrome: reanalysis of a prior phase III trial","volume":"44","author":"Shakoory","year":"2016","journal-title":"Crit Care Med"},{"issue":"11","key":"2026052811220605500_bib115","doi-asserted-by":"crossref","first-page":"e28581","DOI":"10.1002\/pbc.28581","article-title":"The use of anakinra in the treatment of secondary hemophagocytic lymphohistiocytosis","volume":"67","author":"Bami","year":"2020","journal-title":"Pediatr Blood Cancer"},{"issue":"13","key":"2026052811220605500_bib118","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/bloodadvances.2020002328","article-title":"Clinical efficacy of anakinra to mitigate CAR T-cell therapy-associated toxicity in large B-cell lymphoma","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"issue":"9","key":"2026052811220605500_bib119","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1016\/j.clml.2020.04.020","article-title":"Myeloma CAR-T CRS management with IL-1R antagonist anakinra","volume":"20","author":"Jatiani","year":"2020","journal-title":"Clin Lymphoma Myeloma Leuk"},{"issue":"4","key":"2026052811220605500_bib120","doi-asserted-by":"crossref","first-page":"370","DOI":"10.1080\/08880018.2021.1988012","article-title":"Intravenous anakinra for tisagenlecleucel-related toxicities in children and young adults","volume":"39","author":"Dreyzin","year":"2022","journal-title":"Pediatr Hematol Oncol"},{"issue":"1","key":"2026052811220605500_bib121","doi-asserted-by":"crossref","first-page":"e003847","DOI":"10.1136\/jitc-2021-003847","article-title":"Single-center experience using anakinra for steroid-refractory immune effector cell-associated neurotoxicity syndrome (ICANS)","volume":"10","author":"Wehrli","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"1","key":"2026052811220605500_bib122","doi-asserted-by":"crossref","first-page":"e05209","DOI":"10.1002\/ccr3.5209","article-title":"Hemophagocytic lymphohistiocytosis\/macrophage activation syndrome (HLH\/MAS) following treatment with tisagenlecleucel","volume":"10","author":"Mart\u00edn-Rojas","year":"2022","journal-title":"Clin Case Rep"},{"issue":"11","key":"2026052811220605500_bib123","doi-asserted-by":"crossref","first-page":"3398","DOI":"10.1182\/bloodadvances.2022006983","article-title":"Anakinra utilization in refractory pediatric CAR T-cell associated toxicities","volume":"6","author":"Diorio","year":"2022","journal-title":"Blood Adv"},{"issue":"5","key":"2026052811220605500_bib124","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1111\/bjh.18454","article-title":"Hyperinflammatory syndrome resembling haemophagocytic lymphohistiocytosis following axicabtagene ciloleucel and brexucabtagene autoleucel","volume":"199","author":"Porter","year":"2022","journal-title":"Br J Haematol"},{"issue":"7","key":"2026052811220605500_bib125","first-page":"430","article-title":"Anakinra for refractory cytokine release syndrome or immune effector cell-associated neurotoxicity syndrome after chimeric antigen receptor T cell therapy","volume":"29","author":"Gazeau","year":"2023","journal-title":"Transpl Cell Ther"},{"issue":"7","key":"2026052811220605500_bib126","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.1038\/s41591-023-02404-6","article-title":"CD19 CAR T-cell therapy and prophylactic anakinra in relapsed or refractory lymphoma: phase 2 trial interim results","volume":"29","author":"Park","year":"2023","journal-title":"Nat Med"},{"issue":"21","key":"2026052811220605500_bib127","doi-asserted-by":"crossref","first-page":"6785","DOI":"10.1182\/bloodadvances.2023010653","article-title":"A phase 1 study of prophylactic anakinra to mitigate ICANS in patients with large B-cell lymphoma","volume":"7","author":"Strati","year":"2023","journal-title":"Blood Adv"},{"key":"2026052811220605500_bib128","doi-asserted-by":"crossref","first-page":"1157","DOI":"10.3389\/fphar.2018.01157","article-title":"Anakinra therapy for non-cancer inflammatory diseases","volume":"9","author":"Cavalli","year":"2018","journal-title":"Front Pharmacol"},{"issue":"1","key":"2026052811220605500_bib129","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S0009-9236(03)00094-8","article-title":"Pharmacokinetics of anakinra in subjects with different levels of renal function","volume":"74","author":"Yang","year":"2003","journal-title":"Clin Pharmacol Ther"},{"key":"2026052811220605500_bib116","unstructured":"Cincinnati Children's Hospital\n          . CXCL9. Accessed 14 March 2025. https:\/\/www.cincinnatichildrens.org."},{"key":"2026052811220605500_bib117","unstructured":"Machaon Diagnostics. CXCL9. Accessed 10 April 2026. https:\/\/www.machaondiagnostics.com\/."},{"key":"2026052811220605500_bib131","doi-asserted-by":"crossref","first-page":"823847","DOI":"10.3389\/fped.2022.823847","article-title":"Anakinra in paediatric rheumatology and periodic fever clinics: is the higher dose safe?","volume":"10","author":"Fingerhutova","year":"2022","journal-title":"Front Pediatr"},{"issue":"suppl 1","key":"2026052811220605500_bib132","doi-asserted-by":"crossref","first-page":"4858","DOI":"10.1182\/blood-2023-183012","article-title":"Intravenous IL-1 receptor antagonist for prevention of severe immune effector cell-associated neurotoxicity syndrome [abstract]","volume":"142","author":"Park","year":"2023","journal-title":"Blood"},{"issue":"13","key":"2026052811220605500_bib133","doi-asserted-by":"crossref","first-page":"3123","DOI":"10.1182\/bloodadvances.2020002328","article-title":"Clinical efficacy of anakinra to mitigate CAR T-cell therapy\u2013associated toxicity in large B-cell lymphoma [abstract]","volume":"4","author":"Strati","year":"2020","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026052811220605500_bib134","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1182\/blood-2019-123051","article-title":"Corticosteroids do not influence the efficacy and kinetics of CAR-T cells for B-cell acute lymphoblastic leukemia [abstract]","volume":"134","author":"Liu","year":"2019","journal-title":"Blood"},{"issue":"23","key":"2026052811220605500_bib135","doi-asserted-by":"crossref","first-page":"3272","DOI":"10.1182\/blood.2020008865","article-title":"Prognostic impact of corticosteroids on efficacy of chimeric antigen receptor T-cell therapy in large B-cell lymphoma","volume":"137","author":"Strati","year":"2021","journal-title":"Blood"},{"issue":"1","key":"2026052811220605500_bib136","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1038\/s41408-024-01048-0","article-title":"Prognostic impact of corticosteroid and tocilizumab use following chimeric antigen receptor T-cell therapy for multiple myeloma","volume":"14","author":"Costa","year":"2024","journal-title":"Blood Cancer J"},{"issue":"suppl 1","key":"2026052811220605500_bib137","doi-asserted-by":"crossref","first-page":"5382","DOI":"10.1182\/blood-2024-210363","article-title":"Proliferation of a novel CD3neg hyperactivated T-cell population characterizes adult hemophagocytic lymphohistiocytosis and associates with disease activity [abstract]","volume":"144","author":"Rocco","year":"2024","journal-title":"Blood"},{"issue":"S4","key":"2026052811220605500_bib138","first-page":"e31470","article-title":"Persistent expansion of novel hyperactivated T-cell populations characterizes immune effector cell-associated HLH-like syndrome and differentiates it from secondary HLH","volume":"71","author":"Rocco","year":"2024","journal-title":"Pediatr Blood Cancer"},{"issue":"suppl 1","key":"2026052811220605500_bib139","doi-asserted-by":"crossref","first-page":"911","DOI":"10.1182\/blood-2024-198688","article-title":"CD22-directed CAR T cell single cell multiomic features associated with immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome (IEC-HS) [abstract]","volume":"144","author":"Kramer","year":"2024","journal-title":"Blood"},{"issue":"4","key":"2026052811220605500_bib140","doi-asserted-by":"crossref","first-page":"625","DOI":"10.1016\/j.bbmt.2018.12.758","article-title":"ASTCT consensus grading for cytokine release syndrome and neurologic toxicity associated with immune effector cells","volume":"25","author":"Lee","year":"2019","journal-title":"Biol Blood Marrow Transpl"},{"issue":"2","key":"2026052811220605500_bib141","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1158\/2643-3230.BCD-21-0181","article-title":"Blockade or deletion of IFN\u03b3 reduces macrophage activation without compromising CAR T-cell function in hematologic malignancies","volume":"3","author":"Bailey","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"801","key":"2026052811220605500_bib142","doi-asserted-by":"crossref","first-page":"eadp8166","DOI":"10.1126\/scitranslmed.adp8166","article-title":"IFN-\u03b3-resistant CD28 CAR T cells demonstrate increased survival, efficacy, and durability in multiple murine tumor models","volume":"17","author":"Bailey","year":"2025","journal-title":"Sci Transl Med"},{"issue":"7906","key":"2026052811220605500_bib143","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41586-022-04585-5","article-title":"CAR T cell killing requires the IFN\u03b3R pathway in solid but not liquid tumours","volume":"604","author":"Larson","year":"2022\/04\/01 2022","journal-title":"Nature"},{"issue":"suppl 1","key":"2026052811220605500_bib144","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1182\/blood-2024-211980","article-title":"Optimizing the IFN\u03b3 axis improves CAR T-cell potency in AML but not B-ALL [abstract]","volume":"144","author":"Murren","year":"2024","journal-title":"Blood"},{"issue":"9","key":"2026052811220605500_bib145","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1158\/2159-8290.CD-20-1661","article-title":"IFN\u03b3 is critical for CAR T cell-mediated myeloid activation and induction of endogenous immunity","volume":"11","author":"Alizadeh","year":"2021","journal-title":"Cancer Discov"},{"key":"2026052811220605500_bib146","unstructured":"Gamifant. Package insert and medication guide. Food and Drug Administration. Accessed 15 April 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2018\/761107lbl.pdf."},{"issue":"5","key":"2026052811220605500_bib147","doi-asserted-by":"crossref","first-page":"1564","DOI":"10.1182\/bloodadvances.2024013690","article-title":"Emapalumab use in malignancy-associated hemophagocytic lymphohistiocytosis in the United States: the REAL-HLH study","volume":"10","author":"Zoref-Lorenz","year":"2026","journal-title":"Blood Adv"},{"issue":"7","key":"2026052811220605500_bib148","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1080\/1750743X.2025.2509478","article-title":"Emapalumab treatment in rheumatologic disease-associated hemophagocytic lymphohistiocytosis: a plain language summary","volume":"17","author":"Chandrakasan","year":"2025","journal-title":"Immunotherapy"},{"issue":"2","key":"2026052811220605500_bib149","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/art.42985","article-title":"Emapalumab treatment in patients with rheumatologic disease-associated hemophagocytic lymphohistiocytosis in the United States: a retrospective medical chart review study","volume":"77","author":"Chandrakasan","year":"2025","journal-title":"Arthritis Rheumatol"},{"key":"2026052811220605500_bib150","doi-asserted-by":"crossref","first-page":"1543622","DOI":"10.3389\/fonc.2025.1543622","article-title":"Emapalumab for severe cytokine release syndrome in solid tumor CAR-T: a case report","volume":"15","author":"Ruemmele","year":"2025","journal-title":"Front Oncol"},{"issue":"suppl 1","key":"2026052811220605500_bib151","doi-asserted-by":"crossref","first-page":"2076","DOI":"10.1182\/blood-2024-208795","article-title":"CD123-CAR T cells manufactured in the presence of dasatinib induce high grade CRS and\/or IEC-HS without improving efficacy in pediatric patients with recurrent\/refractory leukemia [abstract]","volume":"144","author":"Naik","year":"2024","journal-title":"Blood"},{"issue":"15","key":"2026052811220605500_bib152","doi-asserted-by":"crossref","first-page":"3832","DOI":"10.1182\/bloodadvances.2025016346","article-title":"Fatal recurrence of IEC-HS following autologous stem cell boost in patients receiving BCMA CAR-T cell therapy","volume":"9","author":"Ananth","year":"2025","journal-title":"Blood Adv"},{"issue":"9","key":"2026052811220605500_bib153","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1182\/blood.2025030976","article-title":"CXCL9 as a novel prognostic marker to identify high-risk adults with hemophagocytic lymphohistiocytosis","volume":"147","author":"Rocco","year":"2026","journal-title":"Blood"},{"issue":"2","key":"2026052811220605500_bib154","doi-asserted-by":"crossref","first-page":"90","DOI":"10.1158\/2643-3230.BCD-21-0203","article-title":"Potential role of IFN\u03b3 inhibition in refractory cytokine release syndrome associated with CAR T-cell therapy","volume":"3","author":"McNerney","year":"2022","journal-title":"Blood Cancer Discov"},{"issue":"10","key":"2026052811220605500_bib155","doi-asserted-by":"crossref","first-page":"3439","DOI":"10.3324\/haematol.2023.284784","article-title":"Treatment strategies for progressive immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome: case series","volume":"109","author":"Scala","year":"2024","journal-title":"Haematologica"},{"issue":"4","key":"2026052811220605500_bib156","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1182\/bloodadvances.2022008256","article-title":"Interferon-\u03b3 blockade in CAR T-cell therapy\u2013associated macrophage activation syndrome\/hemophagocytic lymphohistiocytosis","volume":"7","author":"Rainone","year":"2023","journal-title":"Blood Adv"},{"key":"2026052811220605500_bib157","doi-asserted-by":"crossref","first-page":"1563736","DOI":"10.3389\/fimmu.2025.1563736","article-title":"Case report: successful use of emapalumab in adult B-cell acute lymphoblastic leukemia experiencing severe neurotoxicity and hemophagocytic lymphohistiocytosis-like features after CAR-T cell therapy","volume":"16","author":"Manghisi","year":"2025","journal-title":"Front Immunol"},{"issue":"2","key":"2026052811220605500_bib158","doi-asserted-by":"crossref","first-page":"S239","DOI":"10.1016\/j.jtct.2025.01.365","article-title":"Emapalumab for the treatment of toxicities associated with CD19 CAR-T cells in adult patients","volume":"31","author":"Johnson","year":"2025","journal-title":"Transplant Cell Ther"},{"issue":"18","key":"2026052811220605500_bib159","doi-asserted-by":"crossref","first-page":"5603","DOI":"10.1182\/bloodadvances.2023010712","article-title":"Emapalumab for the treatment of refractory cytokine release syndrome in pediatric patients","volume":"7","author":"Schuelke","year":"2023","journal-title":"Blood Adv"},{"issue":"2","key":"2026052811220605500_bib160","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3892\/ol.2024.14817","article-title":"Efficacy of emapalumab in the management of anti-CD19 chimeric antigen receptor T-cell therapy-associated cytokine release syndrome: a report of two cases","volume":"29","author":"Cai","year":"2025","journal-title":"Oncol Lett"},{"issue":"9","key":"2026052811220605500_bib161","first-page":"2998","article-title":"Emapalumab as salvage therapy for adults with malignancy-associated hemophagocytic lymphohistiocytosis","volume":"109","author":"Johnson","year":"2024","journal-title":"Haematologica"},{"issue":"2","key":"2026052811220605500_bib162","doi-asserted-by":"crossref","first-page":"226","DOI":"10.1002\/art.42985","article-title":"Emapalumab treatment in patients with rheumatologic disease-associated hemophagocytic lymphohistiocytosis in the United States: a retrospective medical chart review study","volume":"77","author":"Chandrakasan","year":"2025","journal-title":"Arthritis Rheumatol"},{"issue":"suppl 1","key":"2026052811220605500_bib163","doi-asserted-by":"crossref","first-page":"2534","DOI":"10.1182\/blood-2023-181777","article-title":"Real-world treatment patterns and outcomes among patients with primary hemophagocytic lymphohistiocytosis with and without infection at diagnosis and treated with emapalumab: the REAL-HLH study [abstract]","volume":"142","author":"Allen","year":"2023","journal-title":"Blood"},{"issue":"19","key":"2026052811220605500_bib164","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1911326","article-title":"Emapalumab in children with primary hemophagocytic lymphohistiocytosis","volume":"382","author":"Locatelli","year":"2020","journal-title":"N Engl J Med"},{"issue":"4","key":"2026052811220605500_bib165","doi-asserted-by":"crossref","first-page":"559","DOI":"10.1007\/s40262-023-01225-7","article-title":"Pharmacokinetics and pharmacodynamics of ruxolitinib: a review","volume":"62","author":"Appeldoorn","year":"2023","journal-title":"Clin Pharmacokinet"},{"issue":"suppl 1","key":"2026052811220605500_bib166","doi-asserted-by":"crossref","first-page":"183","DOI":"10.1182\/blood-2023-181922","article-title":"Ruxolitinib promotes clinical responses in large granular lymphocytic leukemia via suppression of JAK\/STAT-dependent inflammatory cascades [abstract]","volume":"142","author":"Moskowitz","year":"2023","journal-title":"Blood"},{"issue":"2","key":"2026052811220605500_bib167","doi-asserted-by":"crossref","first-page":"758","DOI":"10.1111\/bjh.19979","article-title":"JAK2 is a critical therapeutic target in VEXAS syndrome treated with ruxolitinib","volume":"206","author":"Ceccardi","year":"2025","journal-title":"Br J Haematol"},{"issue":"19","key":"2026052811220605500_bib168","doi-asserted-by":"crossref","first-page":"1800","DOI":"10.1056\/NEJMoa1917635","article-title":"Ruxolitinib for glucocorticoid-refractory acute graft-versus-host disease","volume":"382","author":"Zeiser","year":"2020","journal-title":"N Engl J Med"},{"issue":"2","key":"2026052811220605500_bib169","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1182\/blood.2019000761","article-title":"Mechanisms of action of ruxolitinib in murine models of hemophagocytic lymphohistiocytosis","volume":"134","author":"Albeituni","year":"2019","journal-title":"Blood"},{"issue":"11","key":"2026052811220605500_bib170","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1007\/s00432-020-03301-y","article-title":"Ruxolitinib combined with doxorubicin, etoposide, and dexamethasone for the treatment of the lymphoma-associated hemophagocytic syndrome","volume":"146","author":"Zhou","year":"2020","journal-title":"J Cancer Res Clin Oncol"},{"issue":"24","key":"2026052811220605500_bib171","doi-asserted-by":"crossref","first-page":"3493","DOI":"10.1182\/blood.2021014860","article-title":"A study of ruxolitinib response-based stratified treatment for pediatric hemophagocytic lymphohistiocytosis","volume":"139","author":"Zhang","year":"2022","journal-title":"Blood"},{"key":"2026052811220605500_bib172","doi-asserted-by":"crossref","first-page":"614704","DOI":"10.3389\/fimmu.2021.614704","article-title":"Use of the JAK inhibitor ruxolitinib in the treatment of hemophagocytic lymphohistiocytosis","volume":"12","author":"Keenan","year":"2021","journal-title":"Front Immunol"},{"issue":"23","key":"2026052811220605500_bib173","doi-asserted-by":"crossref","first-page":"2386","DOI":"10.1182\/blood.2023021046","article-title":"Differential effects of itacitinib, fedratinib, and ruxolitinib in mouse models of hemophagocytic lymphohistiocytosis","volume":"143","author":"Keenan","year":"2024","journal-title":"Blood"},{"key":"2026052811220605500_bib174","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/j.bbrc.2022.01.070","article-title":"Ruxolitinib reduces severe CRS response by suspending CAR-T cell function instead of damaging CAR-T cells","volume":"595","author":"Xu","year":"2022","journal-title":"Biochem Biophys Res Commun"},{"issue":"23","key":"2026052811220605500_bib175","doi-asserted-by":"crossref","first-page":"6299","DOI":"10.1158\/1078-0432.CCR-20-1739","article-title":"Itacitinib (INCB039110), a JAK1 inhibitor, reduces cytokines associated with cytokine release syndrome induced by CAR T-cell therapy","volume":"26","author":"Huarte","year":"2020","journal-title":"Clin Cancer Res"},{"issue":"2","key":"2026052811220605500_bib176","doi-asserted-by":"crossref","first-page":"1089","DOI":"10.1111\/jcmm.16176","article-title":"Ruxolitinib mitigates steroid-refractory CRS during CAR T therapy","volume":"25","author":"Pan","year":"2021","journal-title":"J Cell Mol Med"},{"issue":"19","key":"2026052811220605500_bib177","doi-asserted-by":"crossref","first-page":"e25786","DOI":"10.1097\/MD.0000000000025786","article-title":"Using JAK inhibitor to treat cytokine release syndrome developed after chimeric antigen receptor T cell therapy for patients with refractory acute lymphoblastic leukemia: a case report","volume":"100","author":"Zi","year":"2021","journal-title":"Medicine (Baltimore)"},{"issue":"14","key":"2026052811220605500_bib178","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.2217\/imt-2020-0116","article-title":"Adjuvant ruxolitinib therapy relieves steroid-refractory cytokine-release syndrome without impairing chimeric antigen receptor-modified T-cell function","volume":"12","author":"Wei","year":"2020","journal-title":"Immunotherapy"},{"issue":"2","key":"2026052811220605500_bib179","doi-asserted-by":"crossref","first-page":"495","DOI":"10.1080\/10428194.2022.2148209","article-title":"Successful treatment of severe cytokine release syndrome after CAR-T therapy by ruxolitinib without compromising CAR-T efficacy","volume":"64","author":"Gu","year":"2023","journal-title":"Leuk Lymphoma"},{"issue":"4","key":"2026052811220605500_bib180","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1182\/blood.2024026586","article-title":"Itacitinib for the prevention of IEC therapy-associated CRS: results from the two-part phase 2 INCB 39110-211 study","volume":"146","author":"Frigault","year":"2025","journal-title":"Blood"},{"issue":"8","key":"2026052811220605500_bib181","doi-asserted-by":"crossref","first-page":"925","DOI":"10.1182\/blood.2019004000","article-title":"How I prevent infections in patients receiving CD19-targeted chimeric antigen receptor T cells for B-cell malignancies","volume":"136","author":"Hill","year":"2020","journal-title":"Blood"},{"issue":"10","key":"2026052811220605500_bib182","first-page":"955","article-title":"Best practice considerations by The American Society of Transplant and Cellular Therapy: infection prevention and management after chimeric antigen receptor T cell therapy for hematological malignancies","volume":"30","author":"Shahid","year":"2024","journal-title":"Transpl Cell Ther"},{"key":"2026052811220605500_bib183","unstructured":"Jakafi. Package insert and medication guide. Food and Drug Administration. Accessed 15 April 2026. https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2017\/202192s015lbl.pdf."},{"issue":"1","key":"2026052811220605500_bib184","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1182\/bloodadvances.2018025858","article-title":"Treatment of refractory hemophagocytic lymphohistiocytosis with emapalumab despite severe concurrent infections","volume":"3","author":"Lounder","year":"2019","journal-title":"Blood Adv"},{"issue":"5","key":"2026052811220605500_bib185","doi-asserted-by":"crossref","first-page":"e360","DOI":"10.1097\/MPH.0000000000002856","article-title":"Combined use of emapalumab with ruxolitinib and dexamethasone as an effective treatment for Epstein-Barr virus-associated hemophagocytic lymphohistiocytosis complicated with multiorgan damage and severe infection","volume":"46","author":"Liang","year":"2024","journal-title":"J Pediatr Hematol Oncol"},{"issue":"suppl 1","key":"2026052811220605500_bib186","doi-asserted-by":"crossref","first-page":"5372","DOI":"10.1182\/blood-2024-201977","article-title":"Efficacy of ruxolitinib in patients with hemophagocytic lymphohistiocytosis: a systematic review [abstract]","volume":"144","author":"Shahzad","year":"2024","journal-title":"Blood"},{"issue":"2","key":"2026052811220605500_bib187","doi-asserted-by":"crossref","first-page":"e35","DOI":"10.1111\/bjh.16155","article-title":"Haemophagocytic lymphohistiocytosis has variable time to onset following CD19 chimeric antigen receptor T cell therapy","volume":"187","author":"Hashmi","year":"2019","journal-title":"Br J Haematol"},{"issue":"2","key":"2026052811220605500_bib188","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1002\/pbc.21039","article-title":"HLH-2004: diagnostic and therapeutic guidelines for hemophagocytic lymphohistiocytosis","volume":"48","author":"Henter","year":"2007","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2026052811220605500_bib189","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1159\/000525576","article-title":"Dramatic recovery after etoposide phosphate infusion for hemophagocytic lymphohistiocytosis\/macrophage activation syndrome following treatment with tisagenlecleucel in a young patient with relapsed acute lymphoblastic leukemia: a case report","volume":"145","author":"Peterlin","year":"2022","journal-title":"Acta Haematol"},{"issue":"23","key":"2026052811220605500_bib190","doi-asserted-by":"crossref","first-page":"7258","DOI":"10.1182\/bloodadvances.2023010546","article-title":"Early response markers predict survival after etoposide-based therapy of hemophagocytic lymphohistiocytosis","volume":"7","author":"Verkamp","year":"2023","journal-title":"Blood Adv"},{"issue":"1","key":"2026052811220605500_bib191","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1186\/s13023-022-02516-1","article-title":"Limited efficacy of tocilizumab in adult patients with secondary hemophagocytic lymphohistiocytosis: a retrospective cohort study","volume":"17","author":"Kim","year":"2022","journal-title":"Orphanet J Rare Dis"},{"issue":"10","key":"2026052811220605500_bib192","doi-asserted-by":"crossref","first-page":"2052","DOI":"10.1038\/s41409-020-0896-3","article-title":"Extracorporeal cytokine adsorption for treating severe refractory cytokine release syndrome (CRS)","volume":"55","author":"Wallet","year":"2020","journal-title":"Bone Marrow Transpl"},{"key":"2026052811220605500_bib193","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.jcrc.2020.02.010","article-title":"Extracorporeal cytokine removal in severe CAR-T cell associated cytokine release syndrome","volume":"57","author":"Stahl","year":"2020","journal-title":"J Crit Care"},{"key":"2026052811220605500_bib194","doi-asserted-by":"crossref","first-page":"111761","DOI":"10.1016\/j.intimp.2024.111761","article-title":"Multi-centers experience using therapeutic plasma exchange for corticosteroid\/tocilizumab-refractory cytokine release syndrome following CAR-T therapy","volume":"130","author":"Pu","year":"2024","journal-title":"Int Immunopharmacol"},{"issue":"12","key":"2026052811220605500_bib195","doi-asserted-by":"crossref","first-page":"e005956","DOI":"10.1136\/jitc-2022-005956","article-title":"Dasatinib for treatment of CAR T-cell therapy-related complications","volume":"10","author":"Baur","year":"2022","journal-title":"J Immunother Cancer"},{"issue":"16","key":"2026052811220605500_bib203","doi-asserted-by":"crossref","first-page":"4348","DOI":"10.1182\/bloodadvances.2024013044","article-title":"CAR T cell toxicities: from bedside to bench how novel toxicities inform laboratory investigations","volume":"8","author":"Perna","year":"2024","journal-title":"Blood Adv"},{"issue":"1","key":"2026052811220605500_bib204","doi-asserted-by":"crossref","first-page":"20357","DOI":"10.1038\/s41598-024-70390-x","article-title":"Transforming kidney transplant monitoring with urine CXCL9 and CXCL10: practical clinical implementation","volume":"14","author":"Tinel","year":"2024","journal-title":"Sci Rep"},{"issue":"1","key":"2026052811220605500_bib205","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1093\/ajcp\/aqae097","article-title":"A semiautomated microfluidic ELISA for the detection of hemophagocytic lymphohistiocytosis biomarkers","volume":"163","author":"Herskovits","year":"2025","journal-title":"Am J Clin Pathol"},{"issue":"9","key":"2026052811220605500_bib206","doi-asserted-by":"crossref","first-page":"2979","DOI":"10.1016\/j.ymthe.2024.03.030","article-title":"Need for standardization of cytokine profiling in CAR T cell therapy","volume":"32","author":"Biery","year":"2024","journal-title":"Mol Ther"},{"issue":"8","key":"2026052811220605500_bib207","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1007\/s00277-017-2993-y","article-title":"Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review","volume":"96","author":"Lin","year":"2017","journal-title":"Ann Hematol"},{"issue":"5","key":"2026052811220605500_bib208","doi-asserted-by":"crossref","first-page":"576","DOI":"10.1111\/ejh.14267","article-title":"CRP and sCD25 help distinguish between adult-onset Still's disease and HLH","volume":"113","author":"Beckett","year":"2024","journal-title":"Eur J Haematol"},{"issue":"1","key":"2026052811220605500_bib209","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/bjh.19803","article-title":"Ruxolitinib-based regimen in children with autoimmune disease or autoinflammatory disease-related haemophagocytic lymphohistiocytosis","volume":"206","author":"Fang","year":"2025","journal-title":"Br J Haematol"},{"issue":"1","key":"2026052811220605500_bib210","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1111\/bjh.19864","article-title":"Goodbye etoposide? Taking the leap to ruxolitinib in haemophagocytic lymphohistiocytosis","volume":"206","author":"Merrill","year":"2025","journal-title":"Br J Haematol"},{"key":"2026052811220605500_bib211","doi-asserted-by":"crossref","first-page":"20406207241245517","DOI":"10.1177\/20406207241245517","article-title":"Improved survival outcomes with anakinra over etoposide-based therapies for the management of adults with hemophagocytic lymphohistiocytosis: a retrospective multicenter research network study","volume":"15","author":"Lee","year":"2024","journal-title":"Ther Adv Hematol"},{"issue":"3","key":"2026052811220605500_bib212","doi-asserted-by":"crossref","first-page":"477","DOI":"10.1111\/ejh.14030","article-title":"Anakinra versus etoposide-based therapy added to high-dose steroids for the treatment of secondary hemophagocytic lymphohistiocytosis","volume":"111","author":"Lee","year":"2023","journal-title":"Eur J Haematol"},{"issue":"suppl 1","key":"2026052811220605500_bib213","doi-asserted-by":"crossref","first-page":"805","DOI":"10.1182\/blood-2024-204230","article-title":"ELA026, a monoclonal antibody targeting signal regulatory protein-\u03b1\/\u03b21\/\u03b3, rapidly controls inflammation and improves 2-month survival in treatment-na\u00efve malignancy-associated hemophagocytic lymphohistiocytosis [abstract]","volume":"144","author":"Maiti","year":"2024","journal-title":"Blood"},{"key":"2026052811220605500_bib214","doi-asserted-by":"crossref","first-page":"1336554","DOI":"10.3389\/fped.2023.1336554","article-title":"Case report: refractory macrophage activation syndrome requiring high-dose anakinra, emapalumab, and etoposide therapy in early-onset systemic juvenile idiopathic arthritis associated with adenoviremia","volume":"11","author":"Slaney","year":"2023","journal-title":"Front Pediatr"},{"issue":"1","key":"2026052811220605500_bib215","doi-asserted-by":"crossref","first-page":"234","DOI":"10.3324\/haematol.2022.281221","article-title":"Response-adjusted regimen combining ruxolitinib, etoposide and dexamethasone (adRED) in adult patients with acute myeloid leukemia-associated hemophagocytic lymphohistiocytosis: a single-center pilot trial","volume":"108","author":"Stalder","year":"2023","journal-title":"Haematologica"},{"issue":"suppl 1","key":"2026052811220605500_bib216","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.1182\/blood-2023-177795","article-title":"A phase 1b study of ELA026, a monoclonal antibody targeting signal regulatory protein-\u03b1\/\u03b21\/\u03b3, in patients with newly diagnosed and previously treated secondary hemophagocytic lymphohistiocytosis [abstract]","volume":"142","author":"Maiti","year":"2023","journal-title":"Blood"},{"issue":"suppl 1","key":"2026052811220605500_bib217","doi-asserted-by":"crossref","first-page":"5379","DOI":"10.1182\/blood-2024-210134","article-title":"Enhancing diagnostic and prognostic strategies in secondary HLH: insights from the Weill-Cornell medicine experience [abstract]","volume":"144","author":"Kaner","year":"2024","journal-title":"Blood"},{"issue":"suppl 1","key":"2026052811220605500_bib218","doi-asserted-by":"crossref","first-page":"3909","DOI":"10.1182\/blood-2023-186948","article-title":"Real-world treatment patterns and outcomes among patients with secondary hemophagocytic lymphohistiocytosis treated with emapalumab in the United States: the REAL-HLH study [abstract]","volume":"142","author":"Allen","year":"2023","journal-title":"Blood"},{"issue":"9","key":"2026052811220605500_bib196","doi-asserted-by":"crossref","first-page":"1574","DOI":"10.1182\/blood-2009-11-253815","article-title":"Serum ferritin is derived primarily from macrophages through a nonclassical secretory pathway","volume":"116","author":"Cohen","year":"2010","journal-title":"Blood"},{"issue":"6","key":"2026052811220605500_bib197","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1002\/pbc.21423","article-title":"Highly elevated ferritin levels and the diagnosis of hemophagocytic lymphohistiocytosis","volume":"50","author":"Allen","year":"2008","journal-title":"Pediatr Blood Cancer"},{"issue":"5","key":"2026052811220605500_bib198","doi-asserted-by":"crossref","first-page":"330","DOI":"10.1016\/1043-4666(90)90062-X","article-title":"The molecular basis for the generation of the human soluble interleukin 2 receptor","volume":"2","author":"Rubin","year":"1990","journal-title":"Cytokine"},{"issue":"23","key":"2026052811220605500_bib199","doi-asserted-by":"crossref","first-page":"14899","DOI":"10.1074\/jbc.272.23.14899","article-title":"Synergy between interferon-\u03b3 and tumor necrosis factor-\u03b1 in transcriptional activation is mediated by cooperation between signal transducer and activator of transcription 1 and NF \u03baB","volume":"272","author":"Ohmori","year":"1997","journal-title":"J Biol Chem"},{"issue":"1","key":"2026052811220605500_bib200","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1136\/annrheumdis-2015-209020","article-title":"Elevated circulating levels of interferon-\u03b3 and interferon-\u03b3-induced chemokines characterise patients with macrophage activation syndrome complicating systemic juvenile idiopathic arthritis","volume":"76","author":"Bracaglia","year":"2017","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"2026052811220605500_bib201","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1111\/bcp.15133","article-title":"Emapalumab in primary haemophagocytic lymphohistiocytosis and the pathogenic role of interferon gamma: a pharmacometric model-based approach","volume":"88","author":"Jacqmin","year":"2022","journal-title":"Br J Clin Pharmacol"},{"issue":"5","key":"2026052811220605500_bib202","doi-asserted-by":"crossref","first-page":"439","DOI":"10.1056\/NEJMoa1709866","article-title":"Tisagenlecleucel in children and young adults with B-cell lymphoblastic leukemia","volume":"378","author":"Maude","year":"2018","journal-title":"N Engl J Med"},{"issue":"suppl 1","key":"2026052811220605500_bib219","doi-asserted-by":"crossref","first-page":"717","DOI":"10.1182\/blood-2025-717","article-title":"Optimal ferritin threshold to diagnose immune effector cell-associated hemophagocytic syndrome (IEC-HS) following CAR-T therapy in relapsed\/refractory multiple myeloma (RRMM) [abstract]","volume":"146","author":"Lee","year":"2025","journal-title":"Blood"},{"issue":"11","key":"2026052811220605500_bib220","doi-asserted-by":"crossref","first-page":"2572","DOI":"10.3324\/haematol.2024.286477","article-title":"Histiocyte Society blueprint for hemophagocytic lymphohistiocytosis research: deciphering underlying disease mechanisms to optimize diagnosis and therapy","volume":"110","author":"Meyer","year":"2025","journal-title":"Haematologica"},{"issue":"11","key":"2026052811220605500_bib221","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41584-021-00694-z","article-title":"Targeting interferon-\u03b3 in hyperinflammation: opportunities and challenges","volume":"17","author":"De Benedetti","year":"2021","journal-title":"Nat Rev Rheumatol"},{"issue":"3","key":"2026052811220605500_bib222","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/s41590-023-01420-5","article-title":"IFN\u03b3 binding to extracellular matrix prevents fatal systemic toxicity","volume":"24","author":"Kemna","year":"2023","journal-title":"Nat Immunol"},{"issue":"7","key":"2026052811220605500_bib223","first-page":"2026","article-title":"Type I interferons: leukemia's old foe in the limelight again","volume":"109","author":"Kumar","year":"2024","journal-title":"Haematologica"},{"key":"2026052811220605500_bib224","doi-asserted-by":"crossref","first-page":"156208","DOI":"10.1016\/j.cyto.2023.156208","article-title":"Interferon-gamma (IFN-\u03b3): Reviewing its mechanisms and signaling pathways on the regulation of endothelial barrier function","volume":"166","author":"Ng","year":"2023","journal-title":"Cytokine"},{"issue":"2","key":"2026052811220605500_bib225","doi-asserted-by":"crossref","first-page":"338","DOI":"10.1002\/eji.200636420","article-title":"IL-18 enhances IFN-gamma-induced production of CXCL9, CXCL10, and CXCL11 in human keratinocytes","volume":"37","author":"Kanda","year":"2007","journal-title":"Eur J Immunol"},{"issue":"11","key":"2026052811220605500_bib226","doi-asserted-by":"crossref","first-page":"e0241719","DOI":"10.1371\/journal.pone.0241719","article-title":"CXCL9, CXCL10, and CXCL11; biomarkers of pulmonary inflammation associated with autoimmunity in patients with collagen vascular diseases-associated interstitial lung disease and interstitial pneumonia with autoimmune features","volume":"15","author":"Kameda","year":"2020","journal-title":"PLoS One"},{"issue":"17","key":"2026052811220605500_bib227","doi-asserted-by":"crossref","first-page":"3457","DOI":"10.1182\/bloodadvances.2021004287","article-title":"IFN-\u03b3 signature in the plasma proteome distinguishes pediatric hemophagocytic lymphohistiocytosis from sepsis and SIRS","volume":"5","author":"Lin","year":"2021","journal-title":"Blood Adv"},{"issue":"6","key":"2026052811220605500_bib228","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1182\/bloodadvances.2023011727","article-title":"Transfusion needs after CAR T-cell therapy for large B-cell lymphoma: predictive factors and outcome (a DESCAR-T study)","volume":"8","author":"Vic","year":"2024","journal-title":"Blood Adv"},{"issue":"suppl 1","key":"2026052811220605500_bib229","doi-asserted-by":"crossref","first-page":"1171","DOI":"10.1182\/blood-2023-186146","article-title":"Granulocyte colony-stimulating factor use in patients with hemophagocytic lymphohistiocytosis: a single center experience [abstract]","volume":"142","author":"Shamaileh","year":"2023","journal-title":"Blood"},{"issue":"9","key":"2026052811220605500_bib230","first-page":"2969","article-title":"Tocilizumab administration in cytokine release syndrome is associated with hypofibrinogenemia after chimeric antigen receptor T-cell therapy for hematologic malignancies","volume":"109","author":"Perl","year":"2024","journal-title":"Haematologica"}],"container-title":["Blood"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/22\/2592\/2522820\/blood_bld-2025-032352-main.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/ashpublications.org\/blood\/article-pdf\/147\/22\/2592\/2522820\/blood_bld-2025-032352-main.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,28]],"date-time":"2026-05-28T15:22:41Z","timestamp":1779981761000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/blood\/article\/147\/22\/2592\/566920\/How-I-treat-HLH-like-toxicities-after-immune"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,28]]},"references-count":229,"journal-issue":{"issue":"22","published-print":{"date-parts":[[2026,5,28]]}},"URL":"https:\/\/doi.org\/10.1182\/blood.2025032352","relation":{},"ISSN":["0006-4971","1528-0020"],"issn-type":[{"value":"0006-4971","type":"print"},{"value":"1528-0020","type":"electronic"}],"subject":[],"published-other":{"date-parts":[[2026,5,28]]},"published":{"date-parts":[[2026,5,28]]}}}